Most experts have raised concerns about the safety and effectiveness of Aduhelm, the Alzheimer’s drug approved last year, as well as the enormous financial consequences, which could add billions of dollars to Medicare spending each year, writes Michael Gusmano, a Hastings Center research scholar and professor of health policy at Lehigh University, in Medpage Today. But there is hope that private and public payers may limit the potential problems by refusing to cover the drug. Medicare’s decision is especially important. Read the article.